Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (2010 - 2026)

Acadia Pharmaceuticals' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 80.84% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $375.6 million (up 64.12% YoY), while the FY2025 annual figure was $391.0 million, up 72.66% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $3.6 million, down from $273.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $273.6 million in Q4 2025, with the low at -$113.1 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is $16.6 million (2024), against an average of $20.2 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 139.9% in 2023, then soared 2897.22% in 2024.
• Acadia Pharmaceuticals' Net Income towards Common Stockholders stood at -$41.6 million in 2022, then soared by 209.97% to $45.8 million in 2023, then soared by 213.87% to $143.7 million in 2024, then jumped by 90.32% to $273.6 million in 2025, then sank by 98.67% to $3.6 million in 2026.
• Business Quant data shows ACAD's Net Income towards Common Stockholders at $3.6 million in Q1 2026, $273.6 million in Q4 2025, and $71.8 million in Q3 2025.